Public Health England, National Infection Service, Salisbury, United Kingdom.
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Front Immunol. 2021 Feb 19;11:599568. doi: 10.3389/fimmu.2020.599568. eCollection 2020.
Ebola viruses are enveloped, single-stranded RNA viruses belonging to the family and can cause Ebola virus disease (EVD), a serious haemorrhagic illness with up to 90% mortality. The disease was first detected in Zaire (currently the Democratic Republic of Congo) in 1976. Since its discovery, Ebola virus has caused sporadic outbreaks in Africa and was responsible for the largest 2013-2016 EVD epidemic in West Africa, which resulted in more than 28,600 cases and over 11,300 deaths. This epidemic strengthened international scientific efforts to contain the virus and develop therapeutics and vaccines. Immunology studies in animal models and survivors, as well as clinical trials have been crucial to understand Ebola virus pathogenesis and host immune responses, which has supported vaccine development. This review discusses the major findings that have emerged from animal models, studies in survivors and vaccine clinical trials and explains how these investigations have helped in the search for a correlate of protection.
埃博拉病毒属于丝状病毒科,是有包膜的单股负链 RNA 病毒,可引起埃博拉病毒病(EVD),这是一种严重的出血性疾病,病死率高达 90%。该疾病于 1976 年在扎伊尔(现为刚果民主共和国)首次被发现。自发现以来,埃博拉病毒在非洲零星暴发,曾导致 2013 年至 2016 年西非最大的埃博拉疫情,该疫情导致超过 28600 例病例和超过 11300 人死亡。这场疫情加强了国际科学界遏制该病毒和开发治疗方法和疫苗的努力。动物模型和幸存者的免疫学研究以及临床试验对于了解埃博拉病毒发病机制和宿主免疫反应至关重要,这支持了疫苗的开发。本文讨论了从动物模型、幸存者研究和疫苗临床试验中得出的主要发现,并解释了这些研究如何帮助寻找保护相关因素。